Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Search results

IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints

Immunovant IMVT reported top-line results from two phase III studies, known as the GO trials, evaluating batoclimab as an investigational treatment for adult patients with active, moderate-to-severe

Zacks 
0 06.04.26